Radium 223 Dichloride
(RAY-dee-um … dy-KLOR-ide)
This page contains brief information about radium 223 dichloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Xofigo |
| | ||
| | ||
| FDA Approved: | | Yes |
FDA Approval for Radium 223 Dichloride
Use in CancerRadium 223 dichloride is approved to treat:
- Prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is used in patients whose disease has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs.
Radium 223 dichloride is also being studied in the treatment of other types of cancer.
More About Radium 223 DichlorideDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research ResultsAlso in the News: Radium-223 Improves Survival in Men With Metastatic Prostate Cancer - Information about the use of this drug to treat cancer.
Clinical Trials Point to New Options for Advanced Prostate Cancer - Information about the use of this drug to treat cancer.
Clinical Trials Accepting PatientsFind Clinical Trials for Radium 223 Dichloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top